NuPathe shares were down 51% to $1.99 in pre-market trading.
NuPathe's Zelrix is a patch that uses electric current (via a small battery and chip) to actively push the commonly used migraine medicine sumatriptan through the skin and into the patient's bloodstream.
The U.S. Food and Drug Administration rejected Zelrix, citing lingering questions and concerns about manufacturing and safety, NuPathe said, adding that additional studies may be conducted to address the issues raised by FDA.NuPathe plans to meet with FDA to discuss ways it can address FDA's concerns, but the company offered no timeline, only saying that Zelrix will not be launched in the first half of 2012, as previously expected. NuPathe shares were halted Monday afternoon at $4.05 a share. The company had $36 million, or $2.46 a share, in cash at the end of the second quarter. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV